Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8573)	2/1/1999 8:38:00 PM
From: Arthur Radley	Read Replies (3) \| Respond to of 17367

Got in the mail today a solicitation letter from Michael Murphy to subscribe to his newsletter. On the cover page he states the following...5 super-hot biotech companies. One is about to unleash new super-antibiotics that kill even the most "resistant" bacteria. Hum! I wonder who he is talking about.

To: Bluegreen who wrote (8573)	2/1/1999 8:46:00 PM
From: aknahow	Respond to of 17367

In addition SCIOS rose over $4 intraday and volume was 10 times normal. But the real difference is how much of a share of the drug belongs to SCIOS and how much belongs to Bayer? So far 100% of Neuprex for all applications belongs to XOMA. For some reason biotechs get away not disclosing vital information regarding partnerships, royalties and etc. This situation stinks. Biotech investors put up with it when we were in a biotech boom, but they should not now. Biotechs that want to enhance the price of there securities should begin to disclose this information even if not required to.